Example of Journal of Oncology Pharmacy Practice format
Recent searches

Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format Example of Journal of Oncology Pharmacy Practice format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Journal of Oncology Pharmacy Practice — Template for authors

Publisher: SAGE
Categories Rank Trend in last 3 yrs
Pharmacology (medical) #145 of 246 down down by 25 ranks
Oncology #232 of 340 down down by 32 ranks
journal-quality-icon Journal quality:
Medium
calendar-icon Last 4 years overview: 746 Published Papers | 1601 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 21/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Springer

Quality:  
High
CiteRatio: 5.5
SJR: 1.112
SNIP: 0.926
open access Open Access

Springer

Quality:  
High
CiteRatio: 5.6
SJR: 1.254
SNIP: 0.855
open access Open Access
recommended Recommended

Springer

Quality:  
High
CiteRatio: 7.3
SJR: 1.697
SNIP: 1.019
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 4.1
SJR: 0.757
SNIP: 1.078

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

2.1

16% from 2019

CiteRatio for Journal of Oncology Pharmacy Practice from 2016 - 2020
Year Value
2020 2.1
2019 2.5
2018 2.9
2017 2.9
2016 2.3
graph view Graph view
table view Table view

0.548

24% from 2019

SJR for Journal of Oncology Pharmacy Practice from 2016 - 2020
Year Value
2020 0.548
2019 0.442
2018 0.63
2017 0.59
2016 0.546
graph view Graph view
table view Table view

0.743

28% from 2019

SNIP for Journal of Oncology Pharmacy Practice from 2016 - 2020
Year Value
2020 0.743
2019 1.038
2018 0.733
2017 0.84
2016 0.832
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has decreased by 16% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 24% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has decreased by 28% in last years.
  • This journal’s SNIP is in the top 10 percentile category.
Journal of Oncology Pharmacy Practice

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

SAGE

Journal of Oncology Pharmacy Practice

Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (...... Read More

Pharmacology (medical)

Oncology

Medicine

i
Last updated on
20 Jun 2020
i
ISSN
1078-1552
i
Impact Factor
High - 1.735
i
Acceptance Rate
Not provided
i
Frequency
Not provided
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SageV
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M and Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 1982; 25(7): 4515–4532. URL 10.1103/PhysRevB.25.4515.

Top papers written in this journal

Journal Article DOI: 10.1177/1078155217745144
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.

Abstract:

BackgroundImmune checkpoint inhibitors are poised to revolutionize the management of a growing number of malignancies. Unfortunately, the management of steroid-refractory immune mediated adverse events is based on a paucity of randomized data and limited to single center experiences. Our initial experience with the IL-6 recep... BackgroundImmune checkpoint inhibitors are poised to revolutionize the management of a growing number of malignancies. Unfortunately, the management of steroid-refractory immune mediated adverse events is based on a paucity of randomized data and limited to single center experiences. Our initial experience with the IL-6 receptor antagonist tocilizumab showed clinical improvement in a wide variety of irAEs. As a result, we adopted the use of tocilizumab for the management of steroid refractory irAEs.MethodsThe character and clinical course of irAEs were abstracted from the medical record and analyzed. The dose of tocilizumab was 4 mg/kg given IV over one hour. C-reactive protein was drawn at first nivolumab infusion and at q two weeks (and with irAEs) thereafter. Clinical improvement was defined as either: documentation of resolution of symptoms or hospital discharge within seven days.ResultsOf the initial 87 patients that were treated with nivolumab, 34 required tocilizumab (39.1%). All patients were on c... read more read less

Topics:

Tocilizumab (55%)55% related to the paper, Nivolumab (53%)53% related to the paper
220 Citations
Journal Article DOI: 10.1177/1078155206069242
Management of hand-foot syndrome induced by capecitabine.
Sarah M Gressett1, Brad L Stanford1, Fred Hardwicke1

Abstract:

Introduction. Capecitabine (Xeloda®) is a systemic prodrug of 5-fluorouracil (5-FU), which is administered in an oral formulation. Hand-foot syndrome (HFS) has proven to be a chronic dose-limiting toxicity of capecitabine, leading to significant morbidity in patients receiving this agent. The purpose of this review is to defi... Introduction. Capecitabine (Xeloda®) is a systemic prodrug of 5-fluorouracil (5-FU), which is administered in an oral formulation. Hand-foot syndrome (HFS) has proven to be a chronic dose-limiting toxicity of capecitabine, leading to significant morbidity in patients receiving this agent. The purpose of this review is to define the pathophysiology, risk factors, incidence and management of capecitabine-induced HFS.Methods. Literature for this review article was collected from the following databases: PubMed, CINAHL, and the proceedings of the American Society of Clinical Oncology (ASCO) confined to the years 1995-2006. The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda®, colorectal cancer, and metastatic breast cancer.Results. HFS associated with capecitabine is a serious dose-limiting toxicity. Incidence of grade 3/4 toxicity is of extreme significance, and introduces the need for dose reductions and/or interruptions in capecitabin... read more read less

Topics:

Capecitabine (67%)67% related to the paper
147 Citations
Journal Article DOI: 10.1191/1078155205JP155OA
Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature.

Abstract:

Objective. A systematic review and meta-analysis was conducted to test the hypothesis that oncology health care workers are at an increased risk of cancer, reproductive complications and acute toxic events.Design. A structured literature search of Index Medicus/MEDLINE, CINAHL, EMBASE, the Cochrane Database of Systematic Revi... Objective. A systematic review and meta-analysis was conducted to test the hypothesis that oncology health care workers are at an increased risk of cancer, reproductive complications and acute toxic events.Design. A structured literature search of Index Medicus/MEDLINE, CINAHL, EMBASE, the Cochrane Database of Systematic Reviews and Healthstar was performed from 1966 to December 2004 for human epidemiological studies evaluating the risk of toxic events in health care workers exposed to cytotoxic drugs. Raw data and adjusted odds ratios (OR) reported in eligible studies were combined using a random effects model to calculate point estimates and 95% confidence intervals (CI) for each potential risk outcome.Main outcome measures. Adjusted OR for congenital malformations, stillbirths and spontaneous abortions among health care workers exposure to cytotoxic agents compared to a non-exposed control group.Results. The systematic review identified 14 studies evaluating the outcomes of interest, seven of which wer... read more read less

Topics:

Systematic review (60%)60% related to the paper, Health care (55%)55% related to the paper, Meta-analysis (53%)53% related to the paper, MEDLINE (52%)52% related to the paper, Odds ratio (51%)51% related to the paper
142 Citations
open accessOpen access Journal Article DOI: 10.1177/1078155210361431
Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device
Paul J. M. Sessink, Thomas H. Connor1, James A Jorgenson2, Timothy G Tyler

Abstract:

Purpose Surface contamination with the antineoplastic drugs cyclophosphamide, ifosfamide, and 5-fluorouracil was compared in 22 US hospital pharmacies following preparation with standard drug preparation techniques or the PhaSeal® closed-system drug transfer device (CSTD). Purpose Surface contamination with the antineoplastic drugs cyclophosphamide, ifosfamide, and 5-fluorouracil was compared in 22 US hospital pharmacies following preparation with standard drug preparation techniques or the PhaSeal® closed-system drug transfer device (CSTD). read more read less

Topics:

Hospital pharmacy (55%)55% related to the paper
View PDF
138 Citations
Journal Article DOI: 10.1177/1078155210378913
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.

Abstract:

Tyrosine kinase is a key enzyme activity utilized in many intracellular messaging pathways. Understanding the role of particular tyrosine kinases in malignancies has allowed for the design of tyrosine kinase inhibitors (TKIs), which can target these enzymes and interfere with downstream signaling. TKIs have proven to be succe... Tyrosine kinase is a key enzyme activity utilized in many intracellular messaging pathways. Understanding the role of particular tyrosine kinases in malignancies has allowed for the design of tyrosine kinase inhibitors (TKIs), which can target these enzymes and interfere with downstream signaling. TKIs have proven to be successful in the treatment of chronic myeloid leukemia, renal cell carcinoma and gastrointestinal stromal tumor, and other malignancies. Scattered reports have suggested that these agents appear to affect blood glucose (BG). We retrospectively studied the BG concentrations in diabetic (17) and nondiabetic (61) patients treated with dasatinib (8), imatinib (39), sorafenib (23), and sunitinib (30) in our clinical practice. Mean declines of BG were dasatinib (53 mg/dL), imatinib (9 mg/dL), sorafenib (12 mg/dL), and sunitinib (14 mg/dL). All these declines in BG were statistically significant. Of note, 47% (8/17) of the patients with diabetes were able to discontinue their medications, including insulin in some patients. Only one diabetic patient developed symptomatic hypoglycemia while on sunitinib. The mechanism for the hypoglycemic effect of these drugs is unclear, but of the four agents tested, c-kit and PDGFRβ are the common target kinases. Clinicians should keep the potential hypoglycemic effects of these agents in mind; modification of hypoglycemic agents may be required in diabetic patients. These results also suggest that inhibition of a tyrosine kinase, be it c-kit, PDGFRβ or some other undefined target, may improve diabetes mellitus BG control and it deserves further study as a potential novel therapeutic option. read more read less

Topics:

Sunitinib (67%)67% related to the paper, Imatinib mesylate (62%)62% related to the paper, Dasatinib (61%)61% related to the paper, Tyrosine kinase (57%)57% related to the paper, Sorafenib (55%)55% related to the paper
View PDF
136 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Journal of Oncology Pharmacy Practice.

It automatically formats your research paper to SAGE formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Journal of Oncology Pharmacy Practice format uses SageV citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Journal of Oncology Pharmacy Practice in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Journal of Oncology Pharmacy Practice guidelines and auto format it.

2. Do you follow the Journal of Oncology Pharmacy Practice guidelines?

Yes, the template is compliant with the Journal of Oncology Pharmacy Practice guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Journal of Oncology Pharmacy Practice?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Journal of Oncology Pharmacy Practice citation style.

4. Can I use the Journal of Oncology Pharmacy Practice templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Journal of Oncology Pharmacy Practice.

5. Can I use a manuscript in Journal of Oncology Pharmacy Practice that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Journal of Oncology Pharmacy Practice that you can download at the end.

6. How long does it usually take you to format my papers in Journal of Oncology Pharmacy Practice?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Journal of Oncology Pharmacy Practice.

7. Where can I find the template for the Journal of Oncology Pharmacy Practice?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal of Oncology Pharmacy Practice's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Journal of Oncology Pharmacy Practice's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Journal of Oncology Pharmacy Practice an online tool or is there a desktop version?

SciSpace's Journal of Oncology Pharmacy Practice is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Journal of Oncology Pharmacy Practice?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Journal of Oncology Pharmacy Practice?”

11. What is the output that I would get after using Journal of Oncology Pharmacy Practice?

After writing your paper autoformatting in Journal of Oncology Pharmacy Practice, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Journal of Oncology Pharmacy Practice's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Journal of Oncology Pharmacy Practice?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Journal of Oncology Pharmacy Practice. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Journal of Oncology Pharmacy Practice?

The 5 most common citation types in order of usage for Journal of Oncology Pharmacy Practice are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Journal of Oncology Pharmacy Practice?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal of Oncology Pharmacy Practice's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Journal of Oncology Pharmacy Practice in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Journal of Oncology Pharmacy Practice Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Journal of Oncology Pharmacy Practice formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template